Advertisement

Chinese Journal of Cancer Research

, Volume 10, Issue 1, pp 9–15 | Cite as

Induction of immune response by IL-6 gene-modified leukemia cells

  • Cao Xuetao 
  • Ge Lingfu 
  • Ju DianWen 
  • Yu Yizhi 
  • Tao Qun 
  • Zhang Weiping 
Gene Therapy
  • 24 Downloads

Abstract

Human IL-6 gene was transduced into FBL-3 murine erythroleukemia cellsin vitro by calcium phosphate co-participation. After selection in the presence of G418, limiting dilution and biological activity assay, G418 resistant clone that secreted the highest level of IL-6 (225.6 U/ml) was selected out of 24 IL-6-secreting clones. The FBL-3 cells secreting the highest level of IL-6 (FBL-3-IL-6) showed decreased growth potential and clonogenicityin vitro. Inhibition of cell growth and clone formation was found to be closely related to the level of IL-6 secretion. FBL-3-IL-6 cells grew more slowly than wild-type FBL-3 leukemia cells and FBL-3 cells secreting lower level of IL-6 (21.3 U/ml) when inoculated s.c. into C57BL/6 mice. The mice inoculated with FBL-3-IL-6 cells showed prolonged survival period than those inoculated with control leukemia cells. Increased cytotoxic activities of splenic NK and CTL were found in mice inoculated with FBL-3-IL-6 cells. The secretions of IL-2, TNF and GM-CSF from murine splenocytes were also found to be greatly elevated after the inoculation of FBL-3-IL-6 leukemia cells. These data suggested that transduction of IL-6 gene into FBL-3 cells magnificently decreased the tumorigenicity and increased the immunogenicity of the leukemia cells, could induce specific and nonspecific antitumor immune responses. IL-6 gene-modified leukemia cells might be of great interests to be used as vaccine for the treatment of leukemia.

Key words

IL-6 immunotherapy gene therapy leukemia tumorigenicity immunogenicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson WF. Gene therapy for cancer. Hum Gene Ther 1994; 5:1.PubMedCrossRefGoogle Scholar
  2. 2.
    Colombo MP, Forni G. Cytokine gene transfer into tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48.PubMedCrossRefGoogle Scholar
  3. 3.
    Muller JJ, Mclntosh Jk, Jablons DM, et al. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 1990; 171: 629.CrossRefGoogle Scholar
  4. 4.
    Gallahger G, Stimson WH, Findlay J, et al. Interleukin 6 enhances the induction of human lymphokine activated killer cells. Cancer Immunol Immunother 1990; 31:49.CrossRefGoogle Scholar
  5. 5.
    Givon T, Slavin S, Haran-Ghera N, et al. Antitumor effects of human recombinant interleukin 6 on acute myloid leukemia in mice and in cell cultures. Blood 1992; 79:2392.PubMedGoogle Scholar
  6. 6.
    Nebber J, Rosenberg SA. Phase I studies of the pharmacokinetic, toxicities and biological effects of interleukin-6 in patients with refractory advanced malignancies. J Immunother 1993; 13:74.Google Scholar
  7. 7.
    1994; 10(5): 289.Google Scholar
  8. 8.
    Sun WH, Kreisle RA, Phillips AW, et al.In vivo and in vitro characteristics of interleukin-6-transfected B16 melanoma cells. Cancer Res 1992; 52:5412.PubMedGoogle Scholar
  9. 9.
    Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutics competence against parental metastatic cells. Cancer Res, 1992;52:3679–3686PubMedGoogle Scholar
  10. 10.
    Ohe Y, Podack ER, Olsen KJ, et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumor growth rate but cause weight loss and shorten survival in syngenic mice. Br J Cancer 1993;67:939–944PubMedGoogle Scholar
  11. 11.
    Mullen CA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with IL-6 gent exhibit reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Cancer Res 1992; 52: 6020.PubMedGoogle Scholar
  12. 12.
    Dougherty GJ, Thacker JD, Lavey RS, et al. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growthin vivo. Cancer Immunol Immunother 1994; 38:339.PubMedCrossRefGoogle Scholar
  13. 13.
    Cao X, Zhang W, Gu S, et al. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2. J Cancer Res Clin Oncol 1996; 121:721.CrossRefGoogle Scholar

Copyright information

© Chinese Journal of Cancer Research 1998

Authors and Affiliations

  • Cao Xuetao 
    • 1
  • Ge Lingfu 
    • 1
  • Ju DianWen 
    • 1
  • Yu Yizhi 
    • 1
  • Tao Qun 
    • 1
  • Zhang Weiping 
    • 1
  1. 1.Department of ImmunologySecond Military Medical UniversityShanghai

Personalised recommendations